- TV Footage
- Integrated Annual Reports
- Quarterly Reports
- Bayer Magazine
- BEENOW Magazine
- Farming’s Future Magazine
- research Magazine
- technology solutions Magazine
- From Molecules to Medicine
- From Molecules to Veterinary Medicines Brochure
- Integrated Weed Management
- Names | Figures | Facts
- Transfers of Value to Physicians Brochure
- Newsletter Overview
- Social Media
- Media Contact
Leverkusen, February 27, 2018 – The Supervisory Board of Bayer AG today approved the Board of Management's recommendation that a dividend payment for fiscal 2017 of 2.80 (2016: 2.70) euros per share entitled to the dividend be proposed to the Annual Stockholders’ Meeting on May 25, 2018. “We thus want to increase the dividend for the eighth consecutive time,” said Bayer CEO Werner Baumann.
With 826.95 million shares entitled to the dividend, the total dividend payment would amount to 2.315 (2016: 2.233) billion euros, an increase of 3.7 percent. Should the capital stock be increased prior to the Annual Stockholders’ Meeting 2018 in connection with the acquisition of Monsanto, the new shares would carry dividend rights for 2017. The total dividend payment would increase accordingly.
The Bayer Group’s consolidated financial statements for 2017 will be published on February 28, 2018 and will be discussed at the Financial News Conference later that day.
For more information go to www.bayer.com.
Follow us on Twitter: twitter.com/BayerPresse_DE
Cautionary Statements Regarding Forward-Looking Statements
Certain statements contained in this communication may constitute “forward-looking statements.” Actual results could differ materially from those projected or forecast in the forward-looking statements. The factors that could cause actual results to differ materially include the following: uncertainties as to the timing of the transaction; the possibility that the parties may be unable to achieve expected synergies and operating efficiencies in the merger within the expected time-frames or at all and to successfully integrate Monsanto’s operations into those of Bayer; such integration may be more difficult, time-consuming or costly than expected; revenues following the transaction may be lower than expected; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) may be greater than expected following the announcement of the transaction; the retention of certain key employees at Monsanto; risks associated with the disruption of management’s attention from ongoing business operations due to the transaction; the conditions to the completion of the transaction may not be satisfied, or the regulatory approvals required for the transaction may not be obtained on the terms expected or on the anticipated schedule; the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the merger; the impact of the refinancing of the loans taken out for the transaction, the impact of indebtedness incurred by Bayer in connection with the transaction and the potential impact on the rating of indebtedness of Bayer; the effects of the business combination of Bayer and Monsanto, including the combined company’s future financial condition, operating results, strategy and plans; other factors detailed in Monsanto’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended Thursday, August 31, 2017 and Monsanto’s other filings with the SEC, which are available at http://www.sec.gov and on Monsanto’s website at www.monsanto.com; and other factors discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. Bayer and Monsanto assume no obligation to update the information in this communication, except as otherwise required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date.